MedTrace Logo

MEN-10755 in Treating Patients With Solid Tumors

NCT00003982 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-07-11

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of MEN-10755 in treating patients who have solid tumors.

Conditions

  • Testicular Germ Cell Tumor
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

sabarubicin

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Emma Geertruida Elisabeth De Vries, MD, PhD · University Medical Center Groningen

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30

Countries

  • Austria
  • Belgium
  • Denmark
  • France
  • Germany
  • Netherlands
  • Norway
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003982 on ClinicalTrials.gov